Inspire2Live
  • Home
  • About us
    • The patient’s voice
      • Origin story of Inspire2live
      • Mission & vision
      • How we work
      • What sets us apart
      • Partners
      • Social enterprises
      • Funding and financial stewardship
      • Organisation
    • Patient Advocacy
      • What is patient advocacy?
      • Meet our patient advocates
      • Patient stories
      • In memoriam
    • Contact
      • Find us on social media
      • Annual Reports
      • For the media
      • Get in contact
  • Our work
    • Our projects
      • DEEP Diagnostics
      • Access to medicine
      • Cancer registries
      • Discover all our projects
    • Congresses
      • Upcoming congresses
      • Annual congresses
      • Past congresses
    • World Campus
      • About the World Campus
      • World Campus sesssions
  • Our impact
    • Ambassadors
    • Heroes of cancer
    • Achievements
    • Research & development
    • Access and implementation
  • News
  • Join Inspire2live
  • Donate
Select Page
Home > News > In the media > Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
March 29, 2021

https://journals.lww.com/hemasphere/Fulltext/2020/10000/Personalized_Treatment_for_Hematologic_Diseases_in.8.aspx

More news

Join us at our 2026 Annual Congress

December 20th, 2025

READ MORE

Sharing our health data comes with expectations

October 30th, 2025

READ MORE

A new save the date for our Annual Congress

September 25th, 2025

READ MORE

Navigation

Home

The patient’s voice

Patient advocacy

World Campus

Our impact

Research & development

More Inspire2Live

Our mission & vision

How we work

Partners

Congresses

News

ANBI statement

Join us

Donate

As a company

Become a patient advocate

Become a partner

Contact us

Follow on social media



Facebook



Twitter



LinkedIn



YouTube



Instagram

Disclaimer | Privacy statement | Cookie statement | ANBI number: 8220 32 752
Disclaimer | Privacy statement | Cookie statement | ANBI number: 8220 32 752